These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 39387986)
1. Real-world effectiveness and safety of trastuzumab-deruxtecan in Japanese patients with HER2-positive advanced gastric cancer (EN-DEAVOR study). Kawakami H; Nakanishi K; Makiyama A; Konishi H; Morita S; Narita Y; Sugimoto N; Minashi K; Imano M; Inamoto R; Kodera Y; Kume H; Yamaguchi K; Hashimoto W; Muro K; Gastric Cancer; 2024 Oct; ():. PubMed ID: 39387986 [TBL] [Abstract][Full Text] [Related]
2. Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged ≥70 years or with an ECOG performance status of 2 (GFPC 08-2015 ENERGY): a randomised, open-label, phase 3 study. Léna H; Greillier L; Cropet C; Bylicki O; Monnet I; Audigier-Valette C; Falchero L; Vergnenègre A; Demontrond P; Geier M; Guisier F; Hominal S; Locher C; Corre R; Chouaid C; Ricordel C; Lancet Respir Med; 2024 Oct; ():. PubMed ID: 39486424 [TBL] [Abstract][Full Text] [Related]
3. De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab versus docetaxel, carboplatin, trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer (HELEN-006): a multicentre, randomised, phase 3 trial. Chen XC; Jiao DC; Qiao JH; Wang CZ; Sun XF; Lu ZD; Li LF; Zhang CJ; Yan M; Wei Y; Chen B; Feng YQ; Deng M; Ma MD; Plichta JK; He YW; Liu ZZ Lancet Oncol; 2024 Nov; ():. PubMed ID: 39612919 [TBL] [Abstract][Full Text] [Related]
4. Primary lung tumour stereotactic body radiotherapy followed by concurrent mediastinal chemoradiotherapy and adjuvant immunotherapy for locally advanced non-small-cell lung cancer: a multicentre, single-arm, phase 2 trial. Heinzerling JH; Mileham KF; Robinson MM; Symanowski JT; Induru RR; Brouse GM; Corso CD; Prabhu RS; Haggstrom DE; Moeller BJ; Bobo WE; Fasola CE; Thakkar VV; Pal SE; Gregory JM; Norek SL; Begic XJ; Kesarwala AH; Burri SH; Simone CB Lancet Oncol; 2024 Nov; ():. PubMed ID: 39615497 [TBL] [Abstract][Full Text] [Related]
5. Early high-dose cryoprecipitate to reduce mortality in adult patients with traumatic haemorrhage: the CRYOSTAT-2 RCT with cost-effectiveness analysis. Curry N; Davenport R; Thomas H; Fox E; Lucas J; Evans A; Massou E; Sharma R; Shanmugaranjan S; Rourke C; Newton A; Deary A; Dallas N; Fitzpatrick-Creamer C; Podbielski JM; Wade CE; Edwards A; Benger J; Morris S; Cotton BA; Piercy J; Green L; Brohi K; Stanworth S Health Technol Assess; 2024 Nov; 28(76):1-69. PubMed ID: 39545850 [TBL] [Abstract][Full Text] [Related]
6. Tamoxifen for adults with hepatocellular carcinoma. Naing C; Ni H; Aung HH Cochrane Database Syst Rev; 2024 Aug; 8(8):CD014869. PubMed ID: 39132750 [TBL] [Abstract][Full Text] [Related]
7. A multicomponent psychosocial intervention to reduce substance use by adolescents involved in the criminal justice system: the RISKIT-CJS RCT. Coulton S; Nizalova O; Pellatt-Higgins T; Stevens A; Hendrie N; Marchand C; Vass R; Deluca P; Drummond C; Ferguson J; Waller G; Newbury-Birch D Public Health Res (Southampt); 2023 Mar; 11(3):1-77. PubMed ID: 37254608 [TBL] [Abstract][Full Text] [Related]
8. Safety, pharmacokinetics, and pharmacodynamics of LBP-EC01, a CRISPR-Cas3-enhanced bacteriophage cocktail, in uncomplicated urinary tract infections due to Escherichia coli (ELIMINATE): the randomised, open-label, first part of a two-part phase 2 trial. Kim P; Sanchez AM; Penke TJR; Tuson HH; Kime JC; McKee RW; Slone WL; Conley NR; McMillan LJ; Prybol CJ; Garofolo PM Lancet Infect Dis; 2024 Dec; 24(12):1319-1332. PubMed ID: 39134085 [TBL] [Abstract][Full Text] [Related]
9. Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs. Marson AG; Burnside G; Appleton R; Smith D; Leach JP; Sills G; Tudur-Smith C; Plumpton CO; Hughes DA; Williamson PR; Baker G; Balabanova S; Taylor C; Brown R; Hindley D; Howell S; Maguire M; Mohanraj R; Smith PE Health Technol Assess; 2021 Dec; 25(75):1-134. PubMed ID: 34931602 [TBL] [Abstract][Full Text] [Related]
10. Falls prevention interventions for community-dwelling older adults: systematic review and meta-analysis of benefits, harms, and patient values and preferences. Pillay J; Gaudet LA; Saba S; Vandermeer B; Ashiq AR; Wingert A; Hartling L Syst Rev; 2024 Nov; 13(1):289. PubMed ID: 39593159 [TBL] [Abstract][Full Text] [Related]
11. Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone. Lee CC; Chen CW; Yen HK; Lin YP; Lai CY; Wang JL; Groot OQ; Janssen SJ; Schwab JH; Hsu FM; Lin WH Clin Orthop Relat Res; 2024 Dec; 482(12):2193-2208. PubMed ID: 39051924 [TBL] [Abstract][Full Text] [Related]
12. Decitabine, venetoclax, and ponatinib for advanced phase chronic myeloid leukaemia and Philadelphia chromosome-positive acute myeloid leukaemia: a single-arm, single-centre phase 2 trial. Short NJ; Nguyen D; Jabbour E; Senapati J; Zeng Z; Issa GC; Abbas H; Nasnas C; Qiao W; Huang X; Borthakur G; Chien K; Haddad FG; Pemmaraju N; Karrar OS; Nguyen D; Konopleva M; Kantarjian H; Ravandi F Lancet Haematol; 2024 Nov; 11(11):e839-e849. PubMed ID: 39303729 [TBL] [Abstract][Full Text] [Related]
13. Real-World Outcomes of Patients With Malignant Pleural Mesothelioma Receiving a Combination of Ipilimumab and Nivolumab as First- or Later-Line Treatment. Schmid S; Holer L; Gysel K; Koster KL; Rothschild SI; Boos LA; Frehner L; Cardoso Almeida S; Britschgi C; Metaxas Y; Mark M; Froesch P; Janthur WD; Allemann A; Waibel C; Von der Mühll-Schill C; Früh M; Mauti LA JTO Clin Res Rep; 2024 Dec; 5(12):100735. PubMed ID: 39624250 [TBL] [Abstract][Full Text] [Related]
14. Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study. Iyer SP; Sica RA; Ho PJ; Prica A; Zain J; Foss FM; Hu B; Beitinjaneh A; Weng WK; Kim YH; Khodadoust MS; Huen AO; Williams LM; Ma A; Huang E; Ganpule A; Nagar SD; Sripakdeevong P; Cullingford EL; Karnik S; Dequeant ML; Patel JN; He XS; Li Z; He QA; Mendonez JH; Keegan A; Horwitz SM Lancet Oncol; 2024 Nov; ():. PubMed ID: 39617017 [TBL] [Abstract][Full Text] [Related]
15. [Efficacy and safety of eltrombopag in the treatment of primary immune thrombocytopenia: real-world data from a single medical center]. Dong XF; Li YL; Li NB; Lin WN; Wang T; Wang HQ; Li LJ; Qu W; Xing LM; Liu H; Wu YH; Wang GJ; Song J; Guan J; Wang XM; Shao ZH; Fu R Zhonghua Xue Ye Xue Za Zhi; 2024 Mar; 45(3):271-276. PubMed ID: 38716599 [No Abstract] [Full Text] [Related]
17. What Are the Functional, Radiographic, and Survivorship Outcomes of a Modified Cup-cage Technique for Pelvic Discontinuity? Mu W; Xu B; Wahafu T; Wang F; Guo W; Zou C; Cao L Clin Orthop Relat Res; 2024 Dec; 482(12):2149-2160. PubMed ID: 38991223 [TBL] [Abstract][Full Text] [Related]